You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
ANYTIME, ANYPLACE LEARNING FOR CRITICAL CARE
SBC: ACADEMIC EDGE, INC. Topic: N/Acompletion, the entire course will provide a professional certificate with continuing nursing education contact hours or can be transferred as academic credit in an undergraduate-nursing program. The model for the OCPP to be developed in this project has three components: didactic core content, clinical practicum, and a Virtual Center of Best Practices. The core ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
HUMAN MONOCOLONAL ANTIBODIES FOR CNS REMYELINATION
SBC: Acorda Therapeutics, Inc. Topic: N/ADESCRIPTION (provided by applicant): The primary goal of the current research will be to select the best recombinant form of one of two naturally occurring human igM antibodies demonstrated to stimulate remyelination to further develop for clinical testing in inflammatory demyelinating disease, such as MS. These antibodies, designated sHIgM22 and sHIgM46, were isolated by the Rodriquez laboratory ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
ANTI-ANDROGENIC MECHANISM OF A NEW COMPOUND
SBC: ANDROSCIENCE CORPORATION Topic: N/ADESCRIPTION (provided by applicant): Androgen blockage therapy may relieve the symptom of an advanced, localized prostate tumor; however, once the tumor evolves into a hormone-refractory stage, there is no effective treatment. A continuous activation of AR by antiandrogens (used in androgen blockage therapy) or other "nonconventional" agonists may contribute to prostate cancer progression in patie ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
ANTIMICROBIAL COATING FOR BIOFILM INHIBITION
SBC: Biomedical Development Corporation Topic: N/ADescription(provided by applicant): Candida is the third leading cause of catheter-related nosocomial bloodstream infections. Indwelling devices have been shown to support colonization and biofilm formulation by Candida. Intravenous lines are the most frequent indwelling device and are the single most common cause of candidemia. Once a Candida biofilm forms in vivo, removal of the substrate that i ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
NOVEL VEHICLE FOR TOPICAL DELIVERY OF CORTICOSTEROIDS
SBC: Biomedical Development Corporation Topic: N/ADESCRIPTION (provided by applicant): Topical corticosteroids are useful treatment modalities for numerous dermatologic conditions. Most topical corticosteroids are applied in a cream or ointment vehicle, which require multiple applications, are subject to inadvertent removal, and can be cosmetically unacceptable. While efficacy has been shown to be increased with the use of hydrocolloid occlusive ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
SAMPLE PROCESSING CARTRIDGES FOR RAPID PCR TB DETECTION
SBC: CEPHEID Topic: N/ADESCRIPTION (provided by applicant): Conventional methods to identify and test the antibiotic susceptibility of Mycobacterium tuberculosis are both slow and insensitive. Current nucleic acid amplification-based techniques present a partial solution by offering a more rapid result, but these methods require a relatively high degree of technical sophistication. Furthermore, assay sensitivity is oft ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
ENDOVASCULAR EMBOLECTOMY FOR STROKE- EXPERIMENTAL STUDY
SBC: CONCENTRIC-MEDICAL Topic: N/ADESCRIPTION (Adapted from applicant's abstract): The application's long-term objective is to improve the treatment of acute ischemic stroke by using mechanical embolectomy for arterial recanalization. The specific aim of this project is to design and test various versions of the Clot Retriever Device (CRD), a helix shaped nitinol device made to ensnare and retrieve thrombo-emboli from cerebral art ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
PRECISE FUNCTIONAL VISION TARGETED WITH FUNDUS IMAGING
SBC: KILBRIDE PAUL Topic: N/AThe ability to precisely measure retinotopically localized visual function is becoming useful as a technique to objectively assess the outcomes of localized intervention procedures that are currently in practice and/or being developed (such as the use of artificial retina material placed directly on the human retina). The primary objective of this proposal is to enhance and ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
SSDNA EXPRESSION OF TRIPLEX-FORMING OLIGONUCLEOTIDES
SBC: CYTOGENIX, INC. Topic: N/AWe propose here to use a transgenic mouse model containing a reporter gene that has a target region amenable to triplex formation as a test system to determine the in vivo efficacy of intracellular ssDNA generation from a ssDNA expression system. 1. Adenovirus vector construct to deliver ssDNA expression cassette with a triplex-forming sequence. a. A double-stranded DNA (dsDNA) sequence encoding f ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
DEVELOPMENT OF POLY-L-GLUTAMIC ACID PACLITAXEL CONJUGATE
SBC: FEM CADET Topic: N/AChemoradiation improves survival for patients with locally advanced non-small cell lung cancer (NSCLC) over radiotherapy (R) alone. Les than 20% of patients have complete pathologic response to combination therapy. Paclitaxel (TXL) is effective as an anti-tumor agent and a radiosensitizer. Peripheral neurotoxicity and granulocytopenia limit its dosage; acute effects from TXL's infusion include na ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health